Medtronic DBS therapy for epilepsy patients approved in EU
21 September 2010 00:00 in Medical Company Product News
Medtronic has received CE Mark accreditation for its Deep Brain Stimulation (DBS) therapy to be used among refractory epilepsy sufferers.
The medical device company has received European clearance to launch the technology as an adjunctive treatment for partial-onset seizures in adult sufferers of the condition, based on positive data from the recent Sante clinical trial.
DBS therapy has already been approved in both the US and Europe for treatment of the symptoms of essential tremor and advanced Parkinson's disease, as well as being specified in the EU for dystonia and obsessive-compulsive disorder patients.
It is now set to be launched for its new indication in expert epilepsy centres across Europe by the end of 2010.
Tom Tefft, senior vice-president and president of the neuromodulation business at Medtronic, said: "This CE Mark is the first approval by a regulatory agency for the use of DBS therapy in severe epilepsy and provides a new treatment option for patients in Europe."
Earlier this month, the company launched its CareLink Network for Heart Failure, a new patient management solution which makes it easier for doctors to monitor the health of cardiac device users.
Other news stories from 21/09/2010
Related news
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency
